Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“ Oncolytics ” or the “ Company ”), a clinical-stage immunotherapy company developing pelareorep, today announced...
Announced alignment with the U.S. Food and Drug Administration regarding the design of its pivotal study ...
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END
PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and...
Company to launch only current registration trial with an immunotherapy in first-line pancreatic cancer in first half of 2026 Trial design allows flexibility to include...
Announced the formation of its Gastrointestinal Tumor Scientific Advisory Board (SAB), a group of leading ...
Initial members include Dr. Sanjay Goel (Rutgers), Dr. Deva Mahalingam (Northwestern), and Dr. Dirk Arnold (GOBLET study; Asklepios Tumorzentrum Hamburg) Scientific Advisory...
Announced updated results from the single-arm squamous cell anal carcinoma cohort of the GOBLET study ...
Announced it has filed a registration statement on Form F-4 with the Securities and Exchange Commission ...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Oncolytics...